SCHEMBL8385667

SCHEMBL8385667

CCc1ccccc1C(=O)Nc1ccc2occ(C3CCN4CCCC4C3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2R P25116 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
DRD2 P14416 11/20 0.38
HTR2A P28223 10/20 0.38
DRD3 P35462 10/20 0.38
MAOB P27338 2/20 0.38
SLC6A4 P31645 1/20 0.36
MAPT P10636 2/20 0.36
ACKR3 P25106 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30908795 1.00 F2R (0.40) F2RHRH3DRD2HTR2ADRD3
SCHEMBL30909176 0.93 DRD2 (0.38) F2RHRH3DRD2HTR2ADRD3
SCHEMBL8383620 0.93 DRD2 (0.38) F2RHRH3DRD2HTR2ADRD3
SCHEMBL30909206 0.92 DRD2 (0.36) DRD2HTR2ADRD3SLC6A4
SCHEMBL8386459 0.92 DRD2 (0.36) DRD2HTR2ADRD3SLC6A4
SCHEMBL8382998 0.88 RAB9A (0.43) DRD2HTR2ADRD3MAPTNPC1
SCHEMBL30909023 0.88 RAB9A (0.43) DRD2HTR2ADRD3MAPTNPC1
SCHEMBL8382621 0.86 HTR2A (0.41) HRH3DRD2HTR2ADRD3KMT2A
SCHEMBL8385565 0.86 HTR2A (0.44) HRH3DRD2HTR2ADRD3MAPT
SCHEMBL30908902 0.86 HTR2A (0.44) HRH3DRD2HTR2ADRD3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
US-5874427-A MIGRAINE ELI LILLY AND COMPANY (US) 1999-02-23 US disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D F2R 343/4885HRH3 126/4885DRD2 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.